A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus

This is a Phase 1/2a double-blind dose-escalating study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of ARO-INHBE in adult participants with obesity (in Part 1), the safety, tolerability, PK, and PD of multiple doses of ARO-INHBE either as monotherapy, or in combination with tirzepatide, in adult participants with obesity with and without type 2 diabetes mellitus (in Part 2 and Part 3).

NCT Number	NCT06700538
Lead Sponsor	Arrowhead Pharmaceuticals
Conditions	Obesity
Enrollment	180 participants
Start Date	2024-12-04
Primary Completion	2027-09-17 (estimated)
Study Completion	2028-01-17 (estimated)
Updated on ClinicalTrials.gov	2026-06-26